Highrisk pathological subtype associated FAM83AAS1 promotes malignancy and glycolysis of lung adenocarcinoma via miR2023p/HK2 axis.
Oncol Rep
; 49(5)2023 05.
Article
en En
| MEDLINE
| ID: mdl-36960858
ABSTRACT
According to the diverse cellular morphology, lung adenocarcinoma (LUAD) was classified into five pathological subtypes, referred to as follows Highrisk group (micropapillary and solid), intermediaterisk group (acinar and papillary) and lowrisk group (epidic). Nevertheless, little is known about the biological function of long noncoding RNA (lncRNA) in the molecular determination of LUAD histologic patterns. Screening the transcriptional expression data from TCGALUAD, the differentially expressed lncRNA across the divergent pathological subtypes were explored. Pancancer analysis revealed the characteristic of FAM83AAS1, which was also confirmed in the LUAD tissues. The function of FAM83AAS1 was uncovered through the in vitro assays. RNA immunoprecipitation and dualluciferase reporter assays were performed to explore the molecular mechanisms of FAM83AAS1. In the present study, it was identified that the expression of FAM83AAS1 was increased from the lowrisk group to the high, which was associated with a poorer prognosis and higher risk of recurrence. Pancancer analysis revealed that FAM83AAS1 was positively correlated with high tumor mutational burden. Additionally, FAM83AAS1 promoted cell migration, invasion and growth of LUAD cancer cells. Mechanistically, FAM83AAS1 sponged miR2023p to regulate the expression of hexokinase II (HK2) in posttranscription, which facilitated the malignancy and glycolysis. The present study uncovered the biological roles of FAM83AAS1/miR2023p/HK2 axis in regulating malignancy and glycolysis of LUAD, which provided novel avenues to addressing the determination of histologic patterns.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Adenocarcinoma
/
MicroARNs
/
ARN Largo no Codificante
/
Neoplasias Pulmonares
Tipo de estudio:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Oncol Rep
Asunto de la revista:
NEOPLASIAS
Año:
2023
Tipo del documento:
Article